NeuroMetrix (NASDAQ:NURO) Coverage Initiated by Analysts at StockNews.com

Investment analysts at StockNews.com began coverage on shares of NeuroMetrix (NASDAQ:NURO) in a research note issued on Tuesday. The brokerage set a “sell” rating on the medical device company’s stock.

NeuroMetrix Trading Down 0.2 %

Shares of NURO stock opened at $4.04 on Tuesday. NeuroMetrix has a twelve month low of $2.66 and a twelve month high of $4.73. The stock has a fifty day simple moving average of $3.97 and a two-hundred day simple moving average of $3.86. The stock has a market capitalization of $8.25 million, a price-to-earnings ratio of -0.88 and a beta of 2.20.

NeuroMetrix (NASDAQ:NURO) last released its quarterly earnings data on Tuesday, November 5th. The medical device company reported ($0.75) earnings per share for the quarter. NeuroMetrix had a negative return on equity of 42.56% and a negative net margin of 203.71%. The business had revenue of $0.59 million during the quarter. During the same period in the previous year, the business posted ($1.66) earnings per share.

About NeuroMetrix

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.